These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 22152169)

  • 1. Cost-utility analyses of diagnostic laboratory tests: a systematic review.
    Fang C; Otero HJ; Greenberg D; Neumann PJ
    Value Health; 2011 Dec; 14(8):1010-8. PubMed ID: 22152169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Growth and quality of the cost-utility literature, 1976-2001.
    Neumann PJ; Greenberg D; Olchanski NV; Stone PW; Rosen AB
    Value Health; 2005; 8(1):3-9. PubMed ID: 15841889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analyses in diabetes: a systematic review and implications from real-world evidence.
    Zhong Y; Lin PJ; Cohen JT; Winn AN; Neumann PJ
    Value Health; 2015 Mar; 18(2):308-14. PubMed ID: 25773567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement.
    Neumann PJ; Fang CH; Cohen JT
    Pharmacoeconomics; 2009; 27(10):861-72. PubMed ID: 19803540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The State of Cost-Utility Analyses in Asia: A Systematic Review.
    Thorat T; Lin PJ; Neumann PJ
    Value Health Reg Issues; 2015 May; 6():7-13. PubMed ID: 29698196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accuracy, risk and the intrinsic value of diagnostic imaging: a review of the cost-utility literature.
    Otero HJ; Fang CH; Sekar M; Ward RJ; Neumann PJ
    Acad Radiol; 2012 May; 19(5):599-606. PubMed ID: 22342653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in the measurement of health utilities in published cost-utility analyses.
    Brauer CA; Rosen AB; Greenberg D; Neumann PJ
    Value Health; 2006; 9(4):213-8. PubMed ID: 16903990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The adoption of cost-effectiveness acceptability curves in cost-utility analyses.
    Meckley LM; Greenberg D; Cohen JT; Neumann PJ
    Med Decis Making; 2010; 30(3):314-9. PubMed ID: 19773582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The changing face of the cost-utility literature, 1990-2012.
    Neumann PJ; Thorat T; Shi J; Saret CJ; Cohen JT
    Value Health; 2015 Mar; 18(2):271-7. PubMed ID: 25773562
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surveillance of Barrett's oesophagus: exploring the uncertainty through systematic review, expert workshop and economic modelling.
    Garside R; Pitt M; Somerville M; Stein K; Price A; Gilbert N
    Health Technol Assess; 2006 Mar; 10(8):1-142, iii-iv. PubMed ID: 16545207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-utility analysis in spine care: a systematic review.
    Kepler CK; Wilkinson SM; Radcliff KE; Vaccaro AR; Anderson DG; Hilibrand AS; Albert TJ; Rihn JA
    Spine J; 2012 Aug; 12(8):676-90. PubMed ID: 22784806
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnostic tests and algorithms used in the investigation of haematuria: systematic reviews and economic evaluation.
    Rodgers M; Nixon J; Hempel S; Aho T; Kelly J; Neal D; Duffy S; Ritchie G; Kleijnen J; Westwood M
    Health Technol Assess; 2006 Jun; 10(18):iii-iv, xi-259. PubMed ID: 16729917
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using Published Health Utilities in Cost-Utility Analyses: Discrepancies and Issues in Cardiovascular Disease.
    Zhou T; Chen Z; Li H; Xie F
    Med Decis Making; 2021 Aug; 41(6):685-692. PubMed ID: 33813938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Cost-Effectiveness of Rapid Diagnostic Testing for the Diagnosis of Bloodstream Infections with or without Antimicrobial Stewardship.
    Pliakos EE; Andreatos N; Shehadeh F; Ziakas PD; Mylonakis E
    Clin Microbiol Rev; 2018 Jul; 31(3):. PubMed ID: 29848775
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?
    Otero HJ; Rybicki FJ; Greenberg D; Mitsouras D; Mendoza JA; Neumann PJ
    Int J Cardiovasc Imaging; 2010 Aug; 26(6):605-12. PubMed ID: 20446040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology.
    Greenberg D; Earle C; Fang CH; Eldar-Lissai A; Neumann PJ
    J Natl Cancer Inst; 2010 Jan; 102(2):82-8. PubMed ID: 20056956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-utility analyses of clinical preventive services: published ratios, 1976-1997.
    Stone PW; Teutsch S; Chapman RH; Bell C; Goldie SJ; Neumann PJ
    Am J Prev Med; 2000 Jul; 19(1):15-23. PubMed ID: 10865159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family Spillover Effects in Pediatric Cost-Utility Analyses.
    Lavelle TA; D'Cruz BN; Mohit B; Ungar WJ; Prosser LA; Tsiplova K; Vera-Llonch M; Lin PJ
    Appl Health Econ Health Policy; 2019 Apr; 17(2):163-174. PubMed ID: 30350218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.